anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Vasoconstrictor studies performed with VANOS Cream, 0.1% in healthy subjects indicate that it is in the super-high range of potency as compared with other topical corticosteroids; however, similar blanching scores do not necessarily imply therapeutic equivalence.

Application of VANOS Cream, 0.1% twice daily for 14 days in 18 adult patients with plaque-type psoriasis (10–50% BSA, mean 19.6% BSA) showed demonstrable HPA-axis suppression in 2 patients (with 12% and 25% BSA) where the criterion for HPA-axis suppression is a serum cortisol level of less than or equal to 18 micrograms per deciliter 30 minutes after stimulation with cosyntropin (ACTH1–24) (See PRECAUTIONS: General and Pediatric Use).

HPA-axis suppression has not been evaluated in psoriasis patients who are less than 18 years of age. HPA-axis suppression has been evaluated in pediatric patients with atopic dermatitis 12 to 18 years of age (See PRECAUTIONS: Pediatric Use).
FIELD: medicine. SUBSTANCE: invention relates to the use of organospecific homeopathic preparations. Invention proposes organospecific homeopathic preparations as inducing agents of apoptosis that stimulate myeloidous and lymphoidous hemopoiesis stems. This preparation can be used as index of precise selection of preparations for patients of the different pathology. EFFECT: enhanced effectiveness of agent. 2 cl
<P>PROBLEM TO BE SOLVED: To provide a method for preparing biocompatible crosslinked polymers.  <P>SOLUTION: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water-soluble precursors having electrophilic and nucleophilic functional groups reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A proportion of people with fibromyalgia demonstrate small fibre pathology (SFP). However, it is unclear how SFP directly relates to pain phenomenology. Thirty-three individuals with FMS and ten healthy volunteers underwent assessment of SFP and sensory phenotyping using corneal confocal microscopy, validated questionnaires and quantitative sensory testing (QST). Corneal nerve fibre length was used to stratify participants with fibromyalgia into with SFP [SFP+] and without SFP [SFP-]. SFP was detected in 50% of the fibromyalgia cohort. Current pain score and QST parameters did not differ between SFP+ and SFP-. Mechanical pain sensitivity (MPS) demonstrated a significant gain-of-function in the SFP- cohort compared to healthy-volunteers (p = 0.014, F = 4.806, η2 = 0.22). Further stratification revealed a cohort without structural SFP but with symptoms compatible with small fibre neuropathy symptoms and a significant gain in function in MPS (p = 0.020 Chi-square). Additionally, this cohort reported higher scores for both depression (p = 0.039, H = 8.483, η2 = 0.312) and anxiety (p = 0.022, F = 3.587, η2 = 0.293). This study confirms that SFP is present in a proportion of people with fibromyalgia. We also show that in a proportion of people with fibromyalgia, small fibre neuropathy symptoms are present in the absence of structural SFP. Greater mechanical pain sensitivity, depression and anxiety are seen in these individuals.
Mitochondrial dysmorphology/dysfunction follow global cerebral ischemia-reperfusion (GCI/R) injury, leading to neuronal death. Our previous researches demonstrated that Levodopa (L-DOPA) improves learning and memory impairment in GCI/R rats by increasing synaptic plasticity of hippocampal neurons. This study investigates if L-DOPA, used in Parkinson's disease treatment, alleviates GCI/R-induced cell death by enhancing mitochondrial quality. Metabolomics and transcriptomic results showed that GCI/R damage affected the Tricarboxylic acid (TCA) cycle in the hippocampus. The results of this study show that L-DOPA stabilized mitochondrial membrane potential and ultrastructure in hippocampus of GCI/R rats, increased dopamine level in hippocampus, decreased succinic acid level, and stabilized Ca2+ level in CA1 subregion of hippocampus. As a precursor of dopamine, L-DOPA is presumed to improves mitochondrial function in hippocampus of GCI/R rats. However, dopamine cannot cross the blood-brain barrier, so L-DOPA is used in clinical therapy to supplement dopamine. In this investigation, OGD/R models were established in isolated mouse hippocampal neurons (HT22) and primary rat hippocampal neurons. Notably, dopamine exhibited a multifaceted impact, demonstrating inhibition of mitochondrial reactive oxygen species (mitoROS) production, stabilization of mitochondrial membrane potential and Ca2+ level, facilitation of TCA circulation, promotion of aerobic respiratory metabolism, and downregulation of succinic acid-related gene expression. Consistency between in vitro and in vivo results underscores dopamine's significant neuroprotective role in mitigating mitochondrial dysfunction following global cerebral hypoxia and ischemia injury. Supplement dopamine may represent a promising therapy to the cognitive impairment caused by GCI/R injury.
533,808. Heating by chemical action. FRANCIS, H. Nov. 28, 1939, No. 30973. [Class 64 (ii)] Heat is obtained by the reaction of potassium permanganate and glycerine. The reaction may be retarded by the addition of powdered silica or finely ground sand, or accelerated by the addition of aluminium or iron filings. In the application to a heating pad for use in hair waving, a mixture of equal parts of potassium permanganate and silica or sand is placed in an envelope of aluminium foil, one surface of which is perforated but covered on its outer side with removable impervious material such as greaseproof paper or cellulose film or with a non- removable absorbent sheet such as cellulose tissue or absorbent paper. If the impervious covering is used, it is removed before the pad is used and a covering of absorbent cellulose tissue backed by grease- or water-proofed paper is applied. The activating liquid consists of glycerine 3 parts and water 1 part by weight, and this is applied to the absorbent covering from which it filters through the metal foil. The envelope may alternatively be of tin, brass or copper foil, or wholly or partly of paper. One side may be of foil and the other side of perforated impervious paper with a covering of absorbent paper or wholly of absorbent paper. Alternatively, both sides may be of paper, one side being impervious, and the other perforated and covered with an absorbent sheet, and made of absorbent paper.
Tetralogy of Fallot (TOF) occurs in approximately 3 to 5 of every 10,000 live births and is the most common cyanotic congenital heart defect and it exhibits four main features. These features are pulmonary stenosis, right ventricular hypertrophy, overriding aorta and ventricular septal defect. Moreover, since the survival of patients with congenital heart diseases has improved significantly in recent decades, long-term complications should be monitored cautiously. One of these complications is aortic root dilatation, attributed to increased and altered flow through the overriding aorta and an uneven sharing of conotruncal tissue between the aorta and pulmonary artery, particularly in patients who have not undergone early repair.

Despite the concern that TOF patients may harbor aortopathy that can lead to aortic regurgitation, aortic aneurysms, and, potentially, aortic dissection, the scope of the problem remains uncertain. Prevalence estimates of aortic root dilatation have ranged from 15% to 87% with the use of various criteria. Moderate to severe aortic regurgitation (AR) has also been reported in up to 12.5% of adults with TOF and dilated aortic roots. The incidence of aortic dissection and surgical intervention remains unknown. Moreover, features associated with aortic dilatation are not fully understood. Therefore, correlating and predicting vulnerable patients and identifying possible risk factors for aortic root dilatation in TOF patients, will enable more cautious follow-up and earlier intervention, thus decreasing possible morbidity and mortality.
PCT No. PCT/SE93/00684 Sec. 371 Date Feb. 10, 1995 Sec. 102(e) Date Feb. 10, 1995 PCT Filed Aug. 17, 1993 PCT Pub. No. WO94/04033 PCT Pub. Date Mar. 3, 1994The present invention relates to an anti-microbial composition for non-pharmaceutical cleaning of contaminated materials, bodies and surfaces, especially contaminated liquids and gases. The composition comprises at least one anti-microbially active protein which has been isolated from mussels, preferably together with glycogen. A quick test for qualitative testing of possibly contaminated liquids, especially drinking water, is also disclosed. The quick test comprises a test tube containing a predetermined amount of the anti-microbial composition. A predetermined amount of the liquid is added to the test tube, shaken and allowed to sediment. The quality of the liquid is determined by a quality indicator extending along the tube.
Iron deficiency anemia is caused by many pathological conditions like chronic kidney disease (CKD), inflammation, malnutrition and gastrointestinal abnormality. Current treatments that are erythropoiesis stimulating agents (ESAs) and iron supplementation are inadequate and often lead to tolerance and/or toxicity. Desidustat, a prolyl hydroxylase (PHD) inhibitor, is clinically used for the treatment of anemia with CKD. In this study, we investigated the effect of desidustat on iron deficiency anemia (IDA). IDA was induced in C57BL6/J mice by iron deficient diet feeding. These mice were then treated with desidustat (15 mg/kg, PO) and FeSO4 (20 mg/kg) for five weeks and effect of the treatment on hematology, iron homeostasis, and bone marrow histology was observed. Effect of desidustat on iron metabolism in inflammation (LPS)-induced iron deficiency was also assessed. Both, Desidustat and FeSO4, increased MCV (mean corpuscular volume), MCH (mean corpuscular hemoglobin), hemoglobin, and HCT (hematocrit) in blood and increased iron in serum, liver, and spleen. Desidustat increased MCHC (mean corpuscular hemoglobin concentration) while FeSO4 treatment did not alter it. FeSO4 treatment significantly increased iron deposition in liver, and spleen, while desidustat increased iron in circulation and demonstrated efficient iron utilization. Desidustat increased iron absorption, serum iron and decreased hepcidin without altering tissue iron, while FeSO4 increased serum and tissue iron by increasing hepcidin in LPS-induced iron deficiency. Desidustat increased erythroid population, especially iron-dependent polychromatic normoblasts and orthochromatic normoblasts, while FeSO4 did not improve cell architecture. PHD inhibition by desidustat improved iron utilization in iron deficiency anemia, by efficient erythropoiesis.
The isoflavone equol has the ability to mimic estrogen at the receptor level, as well as the ability to mitigate the deleterious effects of dihydrotestosterone (DHT) in vivo, thus resulting in potential health benefits for both men and women. Only an approximated one-third of the global population has the inherent ability to produce equol. Diet and colonic bacterial composition play a large role in natural equol production. The present invention can increase the probability of producing significant quantities of equol in vivo. Experimentation has shown the repeatable and measurable evidence of equol. Data from male test subjects indicates clinically significant positive effects on androgenic alopecia and acne vulgaris.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, and associated morbidity and mortality rates have escalated in recent years. Despite improvements in surveillance and clinical treatment strategies, the prognosis of HCC remains very poor due to high incidence of recurrence and metastasis. Recent clinical studies have provided evidence that circulating tumor cell (CTC) may directly participate in the metastasis cascade in various types of malignancies. The investigators previous data indicated that HCC patients with preoperative CTC levels ≥2 suffered significantly earlier recurrence (within 1 year) than patients with lower levels. However, the benefits of postoperative adjuvant therapies in preventing early recurrence in patients with preoperative CTC ≥2 remain to be elucidated. Transarterial chemoembolisation (TACE) is an effective palliative treatment for HCC. The investigators design a randomised controlled trial evaluating the efficacy of using TACE after hepatectomy to reduce early recurrence rates in HCC patients with preoperative CTC level ≥2.
PURPOSE:To obtain a calcium antagonistic agent having hypotensive action and useful as a safe drug, by using gomisin H, gomisin J, gomisin N or gomisin G as an active component. CONSTITUTION:The objective agent contains gomisin H or formula I, gomisin J of formula II, gomisin N of formula III or gomisin G of formula IV as an active component. The compound of the active component can be produced e.g. by extracting KITAGOMISHI (fruit of Schizandra chinensis, a kind of herb drug) with lower hydrocarbons and removing the solvent and volatile components from the extract. The lower hydrocarbons to be used in the extraction process are e.g. petroleum ether, n-hexane or benzene. The extraction is carried out at a temperature between room temperature and the boiling point of the extraction solvent, preferably under refluxing.
A method of stabilizing and potentiating action of molecules of known anti-angiogenic substances such as Angiostatin® or Endostatin® by using in coupling conjugation with cis-unsaturated fatty acids (c-UFAs) in the treatment of cell proliferative disorders uses c-UFAs chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid in predetermined quantities. Preferably, the c-UFAs are in the form of polyunsaturated fatty acids (PUFAs). Uncontrolled or undesirable angiogenic activity promotes cell proliferative disorders and tumor growth, which can be inhibited by the selective use of PUFAs with anti-angiogenic substances used selectively in conjunction with predetermined anti-cancer drugs. For treatment of glioma, a sodium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance and a selected anti-cancer drug. For a non-glioma type of cell proliferation disorder, a sodium, potassium or lithium salt of a PUFA is preferred to form an admixture with an anti-angiogenic substance. Anti-angiogenic substances envisaged in this invention include Angiostatin®, Endostatin®, platelet factor-4, TNP-470, thalidomide, interleukin-12 and metalloproteinase inhibitors (MMP). A preferred method of administration of the mixture to treat a tumor is intra-arterial administration into an artery which provides the main blood supply for the tumor.
Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
Participants will have a 50% chance of first receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks. After a washout period of 2 weeks they will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
Early diagnosis of nodal metastasis has been shown to impact prognosis for dogs with mast cell tumours (MCT). The objective of this retrospective study was to determine the correlation between computed tomographic characteristics of lymph nodes and histologic nodal metastasis using the HN classification system, in dogs with cutaneous or subcutaneous MCT and regional lymph node(s) removal. Dogs that had removal of MCT and regional lymphadenectomy within 31 days of the initial staging computed tomography (CT) were enrolled. Subjective lymph node characteristics used included margination, loss of fat at hilus, shape of margin, perinodal fat pattern, increase in number of nodes, and pre- and post-contrast heterogeneity. Enhancement, heterogeneity, and short-long axis ratio were calculated. Seventy-one lymph nodes from 37 dogs were included. Generalised linear mixed model of assessment of lymph node was performed twice, with binary outcome [non-metastatic (HN0/1) versus metastatic (HN2/3)] and 4-point scales (HN0-HN3). After blind assessment of 7 characteristics described above, a final subjective interpretation of each lymph node as non-metastatic or metastatic was assigned. A significant correlation was found between final interpretation and prediction of metastasis. Higher HN classification was also significantly correlated with the increased number of nodes and pre- and post-contrast heterogeneity. No correlation was found in short-long axis ratio, calculated heterogeneity, or degree of enhancement. Sensitivity of CT was 35.7%, specificity was 96.6%, and accuracy was 60.5% for nodal metastasis. CT alone cannot be recommended for assessment of metastasis. The use of multiple computed tomographic characteristics may increase accuracy of nodal metastasis detection.
PURPOSE: A system for providing statistical information of an electronic prescription and a method thereof, client terminal device for providing the statistical information of the electronic prescription and a service device for the electronic prescription thereof, and record media recorded a computer program for executing the method for providing the statistical information of the electronic prescription are provided to check the electronic prescription or preparation information of a pharmacy for the electronic prescription, thereby providing area information and a medicines use state. CONSTITUTION: A medical institution terminal device(100/1) issues and transmits an electronic prescription for a user of a patient terminal(100/2). A pharmacy terminal device(100/3) receives the electronic prescription through a network. The pharmacy terminal device generates preparation information for the electronic prescription. An electronic prescription service device(300) provides the received electronic prescription to the pharmacy terminal device. The electronic prescription service device provides the electronic prescription and the preparation information to the patient terminal device or the medical institution terminal device or the pharmacy terminal device. [Reference numerals] (100/1) Client terminal device 1(medical institution terminal); (100/2) Client terminal device 2(patient terminal); (100/3) Client terminal device 3(pharmacy terminal); (300) Electronic prescription service device; (AA) Visiting a pharmacy; (BB) Filling a medicine; (S100) Issuing and storing an electronic prescription; (S102) Transmission; (S104) Storing an authentication key and the electronic prescription; (S106) Obtaining regional information of a medical institution; (S108) SMS transmission; (S110) Requesting and authenticating the electronic prescription; (S114) Transmitting a filling completion message and filling information; (S118) Generating and storing statistical information; (S208) Transmitting the electronic prescription; (SS16) Obtaining regional information of a pharmacy
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to experimental toxicology and can be used for prevention of toxic action of molybdenum in experimental animals in case of chronic poisoning. For this purpose natural sorbent zeolite irlit-1 is introduced via probe into stomach of animals in form of 6% suspension in amount 2.5% of body weight. Sorbent is introduced simultaneously with daily introduction of ammonium molybdate solution via probe into stomach in dose 5 mg/100 g of body weight in terms of metal. ^ EFFECT: method ensures considerable reduction of toxic effect of molybdenum in case of chronic poisoning due to reduction of accumulation and increase of heavy metal excretion from organism. ^ 1 tbl, 1 ex, 1 dwg
STUDY OBJECTIVES: The objectives of this study were to understand the relative comorbidity burden of obstructive sleep apnea (OSA), determine whether these relationships were modified by sex or age, and identify patient subtypes defined by common comorbidities.
METHODS: Cases with OSA and noncases (controls) were defined using a validated electronic health record (EHR)-based phenotype and matched for age, sex, and time period of follow-up in the EHR. We compared prevalence of the 20 most common comorbidities between matched cases and controls using conditional logistic regression with and without controlling for body mass index. Latent class analysis was used to identify subtypes of OSA cases defined by combinations of these comorbidities.
RESULTS: In total, 60,586 OSA cases were matched to 60,586 controls (from 1,226,755 total controls). Patients with OSA were more likely to have each of the 20 most common comorbidities compared with controls, with odds ratios ranging from 3.1 to 30.8 in the full matched set and 1.3 to 10.2 after body mass index adjustment. Associations between OSA and these comorbidities were generally stronger in females and patients with younger age at diagnosis. We identified 5 distinct subgroups based on EHR-defined comorbidities: High Comorbidity Burden, Low Comorbidity Burden, Cardiovascular Comorbidities, Inflammatory Conditions and Less Obesity, and Inflammatory Conditions and Obesity.
CONCLUSIONS: Our study demonstrates the power of leveraging the EHR to understand the relative health burden of OSA, as well as heterogeneity in these relationships based on age and sex. In addition to enrichment for comorbidities, we identified 5 novel OSA subtypes defined by combinations of comorbidities in the EHR, which may be informative for understanding disease outcomes and improving prevention and clinical care. Overall, this study adds more evidence that OSA is heterogeneous and requires personalized management.
CITATION: Te TT, Keenan BT, Veatch OJ, Boland MR, Hubbard RA, Pack AI. Identifying clusters of patient comorbidities associated with obstructive sleep apnea using electronic health records. J Clin Sleep Med. 2024;20(4):521-533.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine, and concerns NGF and TrkA receptor binding inhibiting molecules as prolonged analgesics. Substance of the invention involves application of anti-NgF antibodie, isotype IgG4 inhibiting NGF and TrkA binding and blocking biological TrkA activity for preparing a drug for treatment and/or prevention of chronic pain. A method of treatment of chronic pain is declared also. ^ EFFECT: analgesic effect prolongation. ^ 41 cl, 1 tbl, 6 dwg
In group 2, in addition to SoC, the patients will apply the EDThi dressing (PED-10) on the wound(s) for the first 3 weeks following enrollment followed by Procellera® or EDTlo for additional 3 weeks. The use of dressings will be discontinued anytime if complete wound closure is achieved.